Abstract: In this paper, recursive least-squares linear estimation algorithms are proposed for stochastic systems influenced by uniform quantization, random access protocol (RAP) and deception attacks ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Microsoft’s Copilot generative AI is popping up on the web, in mobile apps, in the Edge browser, and especially in Windows. But just what exactly is it? Here’s everything you need to know. I've been ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

Have you ever thought of the humble SUM function as a secret weapon for advanced analytics? Most Excel users see it as a basic tool for adding numbers, but what if I told you it could do so much more?

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...

Paolo Bicchieri is the associate editor for the Northern California and Pacific Northwest region writing about restaurant and bar trends, coffee and cafes, and pop-ups. If you ask us, the best dim sum ...

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...